GAMMA Investing LLC Grows Position in Charles River Laboratories International, Inc. (NYSE:CRL)

GAMMA Investing LLC grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 52.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 437 shares of the medical research company’s stock after purchasing an additional 151 shares during the quarter. GAMMA Investing LLC’s holdings in Charles River Laboratories International were worth $118,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in CRL. CWM LLC raised its position in shares of Charles River Laboratories International by 52.5% in the first quarter. CWM LLC now owns 1,609 shares of the medical research company’s stock worth $436,000 after acquiring an additional 554 shares during the period. Confluence Investment Management LLC purchased a new position in Charles River Laboratories International during the first quarter worth approximately $26,270,000. Nomura Holdings Inc. acquired a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $241,000. HighPoint Advisor Group LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at approximately $230,000. Finally, PNC Financial Services Group Inc. raised its stake in shares of Charles River Laboratories International by 5.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 11,490 shares of the medical research company’s stock worth $2,716,000 after buying an additional 606 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the transaction, the executive vice president now directly owns 23,276 shares in the company, valued at $5,282,953.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the topic of a number of research analyst reports. Mizuho initiated coverage on shares of Charles River Laboratories International in a research note on Friday, June 7th. They issued a “neutral” rating and a $235.00 price target on the stock. Robert W. Baird cut their target price on shares of Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, May 10th. TD Cowen decreased their price target on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a research note on Monday, May 13th. TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Finally, The Goldman Sachs Group began coverage on Charles River Laboratories International in a research report on Thursday, June 6th. They issued a “buy” rating and a $290.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $256.38.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $211.60 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. The stock’s fifty day moving average is $222.48 and its two-hundred day moving average is $232.55. The firm has a market capitalization of $10.90 billion, a P/E ratio of 24.89, a price-to-earnings-growth ratio of 1.98 and a beta of 1.40. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.05 by $0.22. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $997.24 million. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 11 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).